Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Drug

Zhongsheng Pharma’s RAY1225 Enters Phase III Trial for Obesity/Overweight Treatment

Fineline Cube Jun 20, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the initiation of the multi-center, randomized,...

Company Drug

Dizal’s Phase III Trial Completes Enrollment for Shuwozhe in EGFR Exon20ins NSCLC

Fineline Cube Jun 20, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced the completion of patient enrollment for its...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Company Drug

Wantai Biological Launches Phase III Trial for VZV-7D Varicella Vaccine

Fineline Cube Jun 20, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation of...

Company Drug

MSD Initiates IDeate-Prostate01 Phase III Trial of Ifinatamab Deruxtecan for mCRPC

Fineline Cube Jun 20, 2025

Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in...

Company Drug

Changchun BCHT Gains NMPA Approval for BK-01 Adjuvanted Influenza Vaccine

Fineline Cube Jun 20, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial...

Company Drug Policy / Regulatory

NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...

Company Deals Drug

Beijing Science Sun Pharma Inks RMB20M Drug Tech Transfer Pact for NeoAB33 Project

Fineline Cube Jun 20, 2025

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...

Company Drug Policy / Regulatory

CDE Issues New Requirements for IND Applications of Innovative Drugs

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...

Company Deals

ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets

Fineline Cube Jun 20, 2025

UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...

Company Deals

Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services

Fineline Cube Jun 20, 2025

Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...

Company Drug

Shanghai Innogen’s Diabetes Drug Patent for Efsubaglutide Alfa Fully Invalidated

Fineline Cube Jun 20, 2025

Shanghai Innogen Pharmaceutical Technology Co., Ltd recently had its patent for efsubaglutide alfa (brand name:...

Company Drug

Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease

Fineline Cube Jun 20, 2025

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...

Company Medical Device

Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device

Fineline Cube Jun 20, 2025

German giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the...

Company Drug

Joincare Pharma Gets NMPA Green Light for Pediatric Influenza Drug JKN2301

Fineline Cube Jun 20, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that it has received clinical...

Company Deals

Abbott Partners with Abu Dhabi Department of Health to Localize Pharma Production and Digital Health Solutions

Fineline Cube Jun 20, 2025

US-based health care firm Abbott (NYSE: ABT) this week entered into a partnership with the...

Company Deals

Sanofi and Abu Dhabi Department of Health Collaborate to Accelerate Vaccine Development

Fineline Cube Jun 20, 2025

France major Sanofi (NASDAQ: SNY) this week signed a Memorandum of Understanding (MoU) with the...

Company Drug

Platinum Life Biotech’s Ruibosheng First Prescribed in China for aGVHD Treatment

Fineline Cube Jun 20, 2025

Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing...

Company Drug

MindRank’s MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss

Fineline Cube Jun 20, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb...

Company Drug

Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China

Fineline Cube Jun 19, 2025

Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...

Posts pagination

1 … 141 142 143 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.